Sort
10,766 grants matching “checkpoint inhibitor”
Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma
$272,491Robert Wi Chen · Beckman Research Institute/City Of Hope · P50 · FY2022 · CA
Identifying Inhibitors of the APC/C Using Yeast Mutants
$272,223Daniel J Burke · University Of Virginia · R01 · FY2006 · CA
Mechanism of HTLV-1 Leukemogenesis
$272,069Chou-Zen Giam · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2006 · CA
Targeting Endoplasmic Reticulum Stress Sensor IRE1 to Enhance Chemotherapy Sensitivity in MYC-driven breast cancer
$272,000Xi Chen · Baylor College Of Medicine · P50 · FY2024 · CA
Project 2: Targeting RTK Co-Dependencies in Triple-Negative Breast Cancer
$271,773Thomas Westbrook · Baylor College Of Medicine · P50 · FY2024 · CA
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine
$271,697Kavitha Yaddanapudi · University Of Louisville · P20 · FY2021 · GM
A Novel Pathway Involving ATM, PP1 and I-2
$271,684Sankar Mitra · Methodist Hospital Research Institute · R01 · FY2012 · ES
A Novel Pathway Involving ATM, PP1 and I-2
$271,684Bo Xu · Methodist Hospital Research Institute · R01 · FY2011 · ES
Removing sialic acid ligands of CD28 to enhance T cell cancer immunotherapy
$271,500James C. Paulson · Scripps Research Institute, The · R21 · FY2024 · AI
Mechanisms of resistance to immune therapy in NSCLC
$271,232Qingsheng Li · University Of Louisville · P20 · FY2021 · GM
Aurora-A/BTAK/STK15 Oncoprotein in Mitotic Spindle Assembly and Checkpoint Respon
$271,209Subrata Sen · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA
Oligomannose antigens as conserved immunological targets of Non-Hodgkin lymphomas
$271,185Denong Wang · Sri International · R21 · FY2021 · CA
Understanding how the interaction between Lag3 deficiency and hypercholesterolemia impact anti-tumor immunity and cardiovascular disease in a melanoma model
$271,004Annabelle Rodriguez · University Of Connecticut Sch Of Med/Dnt · R21 · FY2023 · CA
TR&D Project 3
$270,982Jamie Berta Spangler · Johns Hopkins University · P41 · FY2024 · EB
Defining mechanisms of immunotherapy resistance and targeting TIGIT in hepatobiliary cancers
$270,981David Hsieh · Ut Southwestern Medical Center · K08 · FY2025 · CA
Understanding and overcoming Immunotherapy resistance in Pediatric High-Grade Glioma
$270,938Dolores Hambardzumyan · Icahn School Of Medicine At Mount Sinai · R21 · FY2022 · NS
Ribosome Biogenesis and p53 Dependent Cell Cycle Control
$270,929Lester F Lau · University Of Illinois At Chicago · R01 · FY2006 · CA
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine
$270,817Kavitha Yaddanapudi · University Of Louisville · P20 · FY2022 · GM
Exploiting Therapeutic Vulnerabilities
$270,796William A Weiss · Children'S Hospital Of Los Angeles · P01 · FY2018 · CA
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
$270,598Amarnath Natarajan · University Of Nebraska Medical Center · R01 · FY2011 · CA
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
$270,598Amarnath Natarajan · University Of Nebraska Medical Center · R01 · FY2012 · CA
Project 1: Targeting Metabolic Vulnerabilities in Lung Cancer
$270,549Ralph J Deberardinis · Ut Southwestern Medical Center · P50 · FY2022 · CA
Project 1: Targeting Metabolic Vulnerabilities in Lung Cancer
$270,548Ralph J Deberardinis · Ut Southwestern Medical Center · P50 · FY2023 · CA
Metnase, PIKK, and RPA Roles in DNA Damage and Replication Stress Responses
$270,375Jac A Nickoloff · Colorado State University · R01 · FY2016 · GM
Metnase, PIKK, and RPA Roles in DNA Damage and Replication Stress Responses
$270,367Jac A Nickoloff · Colorado State University · R01 · FY2015 · GM